Now take a deep breath: inhaled loxapine for the treatment of acute agitation.
Robert H Howland
Index: J. Psychosoc. Nurs. Ment. Health Serv. 50(1) , 16-8, (2012)
Full Text: HTML
Abstract
Acute agitation in patients with schizophrenia or bipolar disorder is an important clinical management problem. Liquid concentrates, orally disintegrating tablets, and/or intramuscular formulations of several second-generation atypical antipsychotic drugs are available for treating acute agitation. Loxapine is an older first-generation antipsychotic drug that is approved for the treatment of schizophrenia. Staccato(®) loxapine is an investigational device system using a loxapine-coated heat source to administer loxapine by inhalation. Three multicenter, randomized, double-blind, placebo-controlled efficacy and safety studies of Staccato loxapine have been conducted in patients with acute agitation associated with schizophrenia or bipolar disorder. These studies found that inhaled loxapine was rapidly effective and generally well tolerated, although there are potential concerns about adverse pulmonary effects.Copyright 2012, SLACK Incorporated.
Related Compounds
Related Articles:
2012-01-01
[J. Pharm. Biomed. Anal. 58 , 83-93, (2012)]
2011-01-17
[Int. J. Pharm. 403(1-2) , 101-8, (2011)]
2012-03-01
[Int. J. Clin. Pract. 66(3) , 318-25, (2012)]
2011-10-01
[Can. J. Psychiatry. 56(10) , 630-4, (2011)]
2011-02-01
[J. Comput. Aided Mol. Des. 25(2) , 163-9, (2011)]